Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CTSD | P07339 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16418161 | 0.92 | RAB9A (0.56) | RAB9ASMN1; SMN2NPC1ALDH1A1CYP3A4 | |
| SCHEMBL16418160 | 0.92 | RAB9A (0.56) | RAB9ASMN1; SMN2NPC1ALDH1A1CYP3A4 | |
| SCHEMBL9191298 | 0.89 | RAB9A (0.53) | RAB9ASMN1; SMN2NPC1ALDH1A1CYP3A4 | |
| SCHEMBL1146111 | 0.89 | RAB9A (0.52) | RAB9ASMN1; SMN2NPC1ALDH1A1CYP3A4 | |
| SCHEMBL28074773 | 0.87 | RAB9A (0.64) | RAB9ASMN1; SMN2NPC1ALDH1A1CYP3A4 | |
| SCHEMBL7821883 | 0.86 | ALDH1A1 (0.68) | RAB9ASMN1; SMN2NPC1ALDH1A1CYP3A4 | |
| SCHEMBL6572119 | 0.86 | RAB9A (0.63) | RAB9ASMN1; SMN2NPC1ALDH1A1CYP3A4 | |
| SCHEMBL13398677 | 0.85 | HSD17B10 (0.49) | RAB9ASMN1; SMN2NPC1ALDH1A1CYP3A4 | |
| SCHEMBL27512815 | 0.85 | RAB9A (0.59) | RAB9ASMN1; SMN2NPC1ALDH1A1CYP3A4 | |
| SCHEMBL5788249 | 0.84 | RAB9A (0.56) | RAB9ASMN1; SMN2NPC1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1017848-A2 | NUCLEIC ACID SEQUENCE ANALYSIS | Medical Biosystems Ltd. (GB) | 2000-07-12 | — | — | EP | claimed |
| WO-1999005315-A2 | NUCLEIC ACID SEQUENCE ANALYSIS | MEDICAL BIOSYSTEMS LTD. (GB) | 1999-02-04 | — | — | WO | claimed |
| WO-2024152995-A1 | MACROCYCLIC CYCLIN INHIBITORS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 上海海量医药科技有限公司 | 2024-07-25 | — | — | WO | disclosed |
| US-20210060168-A1 | ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATES | ARCTURUS THERAPEUTICS, INC. | 2021-03-04 | — | — | US | disclosed |
| EP-3413921-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABLES | Krantz, Alexander (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139329-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABLES | KRANTZ ALEXANDER (US) | 2017-08-17 | — | — | WO | disclosed |
| EP-2267165-B1 | Nucleic acid sequence analysis | GEN PROBE INC (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2267164-B1 | Nucleic acid sequence analysis | GEN PROBE INC (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-1229133-B1 | Apparatus for nucleic acid sequence analysis | GEN PROBE INC (US) | 2016-03-09 | — | — | EP | disclosed |
| CN-103230389-A | Novel nitrocatechol derivatives having selectin ligand activity | REVOTAR BIOPHARMACEUTICALS AG | 2013-08-07 | — | — | CN | disclosed |
| CN-101374508-B | Novel nitrocatechol derivatives having selectin ligand activity | REVOTAR BIOPHARMACEUTICALS AG | 2013-04-24 | — | — | CN | disclosed |
| EP-0447118-B1 | 3-tetrazolylthiomethyl cephalosporin antibiotics | ZENECA PHARMA SA (FR) | 1995-12-13 | — | — | EP | disclosed |
| EP-0624584-A1 | Piperazine derivatives useful as calmodolin inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-11-17 | — | — | EP | disclosed |
| US-5200404-A | Bactericides | ICI PHARMA (FR) | 1993-04-06 | — | — | US | disclosed |
| EP-0447118-A2 | 3-tetrazolylthiomethyl cephalosporin antibiotics | ZENECA Pharma S.A. (FR) | 1991-09-18 | — | — | EP | disclosed |
| EP-0146787-B1 | INDOLE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND PROCESS FOR THEIR PREPARATION | Dr. Karl Thomae GmbH (DE) | 1988-08-17 | — | — | EP | disclosed |
| US-4616011-A | BRADYCARDIAL AND ANTIISCHEMIC AGENTS; CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1986-10-07 | — | — | US | disclosed |
| US-4584293-A | LOWER HEART RATE AND OXYGEN REQUIREMENT | DR. KARL THOMAE GMBH (DE) | 1986-04-22 | — | — | US | disclosed |
| EP-0161604-A2 | Aminotetralin derivatives, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1985-11-21 | — | — | EP | disclosed |
| EP-0146787-A2 | Indole derivatives, medicaments containing these compounds, and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210060168-A1 | ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATES | ASGR1, FCGR2A, FCGR3B | RAB9A 1401/4885SMN1; SMN2 3266/4885NPC1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.